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o r i g i n a l a r t i c l e
A Role for Antimicrobial Stewardship in Clinical Sepsis Pathways:
a Prospective Interventional Study
John Burston, MBBS, FRACP;1,2 Suman Adhikari, B Pharm, Grad Dip Clin Pharm;2,3 Andrew Hayen, BA(Hons),
M. Biostat, PhD;4,5 Heather Doolan, BN, MPH;6 Melissa L. Kelly, BMed, MPH&TM;1,2 Kathy Fu, MBBS;1,2
Tomas O. Jensen, MD, MSc;1,2 Pamela Konecny, MBBS, MPH, MD(Res)1,2
objective. To evaluate the impact of early infectious diseases (ID) antimicrobial stewardship (AMS) intervention on inpatient sepsis
antibiotic management.
design. Interventional, nonrandomized, controlled study.
setting. Tertiary-care referral hospital, Sydney, Australia.
patients. Consecutive, adult, non–intensive care unit (non-ICU) inpatients triggering an institutional clinical sepsis pathway from May to
August 2015.
intervention. All patients reviewed by an ID Fellow within 24 hours of sepsis pathway trigger underwent case review and clinic file
documentation of recommendations. Those not reviewed by an ID Fellow were considered controls and received standard sepsis pathway care.
The primary outcome was antibiotic appropriateness 48 hours after sepsis trigger.
results. In total, 164 patients triggered the sepsis pathway: 6 patients were excluded (previous sepsis trigger); 158 patients were eligible; 106
had ID intervention; and 52 were control cases. Of these 158 patients, 91 (58%) had sepsis, and 15 of these 158 (9.5%) had severe sepsis. Initial
antibiotic appropriateness, assessable in 152 of 158 patients, was appropriate in 80 (53%) of these 152 patients and inappropriate in 72 (47%) of
these patients. In the intervention arm, 93% of ID Fellow recommendations were followed or partially followed, including 53% of cases in which
antibiotics were de-escalated. ID Fellow intervention improved antibiotic appropriateness at 48 hours by 24% (adjusted risk ratio, 1.24; 95%
confidence interval, 1.04–1.47; P= .035). The appropriateness agreement among 3 blinded ID staff opinions was 95%. Differences in inter-
vention and control group mortality (13% vs 17%) and median length of stay (13 vs 17.5 days) were not statistically significant.
conclusion. Sepsis overdiagnosis and delayed antibiotic optimization may reduce sepsis pathway effectiveness. Early ID AMS improved
antibiotic management of non-ICU inpatients with suspected sepsis, predominantly by de-escalation. Further studies are needed to evaluate
clinical outcomes.
Infect Control Hosp Epidemiol 2017;1–7
Sepsis represents a major international health challenge with
high mortality.1,2 Although early antibiotic therapy is likely to
reduce mortality in severe sepsis,3 recent debate has focused on
the importance of antibiotic appropriateness in addition to
timing.1,4,5 The international ‘surviving sepsis’ campaign
focused on improving outcomes in sepsis.6 In New South
Wales, Australia, the Clinical Excellence Commission (CEC)
introduced statewide clinical sepsis pathways for emergency
departments and subsequently for non–intensive care unit
(non-ICU) inpatient wards in 2014, as part of a quality
improvement program.7 The CEC sepsis pathways promote
performing blood cultures, measuring serum lactate levels,
conducting intravenous fluid resuscitation, and administering
antibiotics within 60 minutes of sepsis recognition.7 The CEC
pathways are based on the Sepsis-2 definitions of sepsis as
infection with 2 or more systemic inflammatory response
syndrome (SIRS) criteria and of severe sepsis as sepsis causing
organ dysfunction.6 The CEC inpatient sepsis pathway was
implemented in this hospital in October 2014 (referred to
hereafter as ‘the sepsis pathway’) following an intensive
preimplementation phase of junior medical officer and nurse
education, resource development within the rapid response
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program, and provision of ward ‘sepsis kits’ containing other-
wise restricted antibiotics.
Preliminary evaluation of our hospital sepsis pathway
implementation revealed that half of the patients who
triggered the pathway did not have sepsis and were frequently
prescribed prolonged broad-spectrum antibiotic courses
requiring infectious disease (ID) antimicrobial stewardship
(AMS) intervention. Overprescription of broad-spectrum
antibiotics was identified as a potential risk to patient safety
and a target for intervention.8 The aim of this study was to
improve antibiotic management for inpatients triggering the
sepsis pathway by early ID case review.
methods
Study Design, Setting and Population
This investigation was an interventional, nonrandomized,
controlled study of adult non-ICU inpatients conducted in a
660-bed tertiary-care referral hospital in Sydney,
Australia. Consecutive patients who triggered the sepsis path-
way between May and August 2015 were enrolled. The inter-
vention was case review within 24 hours of the sepsis pathway
trigger, by an infectious diseases advanced trainee (IDAT), an
ID fellow equivalent trained in sepsis and AMS management
and clinical practice improvement (CPI) methodology.
Application of the plan-do-study-act (PDSA) cycle metho-
dology identified IDAT intervention as the most likely
to be effective.9 Hospitalwide clinical staff education was
undertaken prior to implementation, including training
videos, intranet resources, and empiric sepsis antibiotic
prescribing guide.
The sepsis pathway was triggered when deterioration in a
patient’s vital signs was suspected to be due to sepsis by either
the treating team or by the rapid response medical team.7
Specifically, 2 or more of the following vital signs in the context
of infection would prompt sepsis pathway trigger: respiratory
rate ≤10 or ≥25 respirations per minute, SpO2 <95%, systolic
blood pressure <100mmHg, heart rate ≤50 or ≥120 beats per
minute, altered consciousness or new onset of confusion,
temperature <35.5°C or >38.5°C.7 The trigger time was recor-
ded as the time of the rapid response call or, if no rapid response
was instituted, the time when abnormal vital signs consistent
with sepsis were recognized. The treating team generated an
electronic alert to notify the IDAT of a sepsis pathway case.
The intervention group received an IDAT review within
24 hours either during that working day or the next day so that
timely recommendations for antibiotic management and
investigations could be documented as a handwritten entry in
the patient file. Written acknowledgement of IDAT review by
the treating team was confirmed. A formal ID consulting
process involving a senior ID physician was not undertaken
unless the treating team requested it. No patients had received
ID review prior to enrollment. The control group comprised
those patients who triggered the sepsis pathway (ie, generating
an electronic alert) but did not receive IDAT intervention
due to lack of availability (eg, Saturday trigger or competing
clinical priorities) and received standard care from
their treating team. The electronic alert contained patient
identifying information, sepsis trigger time, ward location and
department without clinical case details; these alerts were
reviewed consecutively by the IDAT as work schedule
permitted. There was no prescreening and, thus, no prioritizing
of alerts. Patients were excluded from the study if they had
previously triggered the sepsis pathway (Figure 1).
The following data were collected retrospectively from the
patient’s electronic medical record and paper files
following discharge or death: baseline demographics at the
time of sepsis trigger, likely source of sepsis, whether blood
cultures and serum lactate were obtained, vital signs and
laboratory data to determine whether SIRS criteria for sepsis
were met and to calculate the APACHE II score for
sepsis severity, and microbiology data at both time points. The
antibiotics prescribed, dose and time of administration,
were recorded for the period immediately prior to,
immediately after the alert, and at 48 hours after the pathway
trigger.
Antibiotic appropriateness was categorized as ‘appropriate,’
‘inappropriate’ or ‘not assessable’ according to National
Antimicrobial Prescribing Survey (NAPS) criteria.10 These
standardized criteria are used nationally in periodic point-
prevalence surveys. They classify prescriptions as ‘appropriate’ if
consistent with local or national therapeutic guidelines11 or
directed by microbiological results, with subcategories of
‘optimal’ and ‘adequate.’ The ‘inappropriate’ classification refers
to antibiotic prescribing where ‘appropriate’ criteria are not
met, with subcategories of ‘suboptimal’ and ‘inadequate.’
Antibiotic appropriateness, was assessed immediately after the
sepsis pathway trigger and at 48 hours after the trigger
(a recommended pathway review time point).7 ‘Inappropriate’
initial antibiotic therapy may be exemplified by an empiric
prescription of cefazolin for presumptive line-related sepsis
when a patient is colonized with MRSA. ‘Appropriate’ initial
antibiotic therapy of pipericillin/tazobactam plus gentamicin
for presumptive severe nosocomial urosepsis would be classi-
fied at 48 hours as ‘inappropriate’ if it was not de-escalated
when ampicillin-susceptible Escherichia coli was isolated from
the urine and bloodstream. The primary outcome was defined
as antibiotic appropriateness at 48 hours post sepsis pathway
trigger. Patients classified as unassessable due to missing clinical
data at the time of IDAT review were excluded from the
appropriateness analysis (Figure 1). Total length of antibiotic
therapy was calculated by combining days of parenteral, oral,
and discharge prescriptions. Secondary outcomes analyzed were
length of therapy, admission to the ICU, formal ID consulta-
tions, length of stay (LOS), and in-hospital mortality.
Interventions recommended by the IDAT and the com-
pliance of the treating team were recorded. Compliance was
defined as ‘followed’ if all recommendations were imple-
mented within 48 hours, ‘partially followed’ if at least 1 but not
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all recommendations were implemented within 48 hours, or
‘not followed.’
The first author was responsible for conducting the IDAT
intervention. Data retrieved from patient electronic records
and paper-based files by a blinded author were assessed sepa-
rately by 2 blinded senior ID physician coauthors to establish
the inter-rater reliability for antibiotic appropriateness, and
the diagnoses of sepsis and severe sepsis. The outcome of any
disagreement between assessors was determined by a con-
sensus decision between the 2 ID physicians.
Data Analysis
Dichotomous baseline and outcome measurements between
groups was compared using a χ2 or Fisher exact test, as appro-
priate. For continuous variables, a t test or aMann-Whitney test
was used as appropriate. For imbalance in baseline character-
istics between the 2 groups, a log-binomial regression model
was fitted adjusting for the variables for which there were
important baseline differences. The primary outcome was
compared in all patients who triggered the sepsis pathway and
in the subgroup identified as having sepsis. To detect a differ-
ence in antibiotic appropriateness at 48 hours between 50% in
the control group and 80% in the intervention group with an α
of 0.05 and 80% power, 45 patients were required in each arm
of the study. Due to limited data from the literature and our
small pilot study to guide sample size calculations, 8 further
controls were enrolled. Data were analyzed using Stata version
14.0 software (StataCorp, College Station, TX).
Ethics
The study was approved by the South Eastern Local Health
District’s Human Research Ethics Committee (HREC 15/039).
results
Participants and Baseline Characteristics
During the 15-week study period, there were 164 referrals for
inpatients who triggered the sepsis pathway. Of these, 111 were
captured by the IDAT intervention and 53 patients
were included as controls (Figure 1). Overall, 5 patients were
excluded in the intervention arm and 1 patient was excluded in
the control arm because they had previously triggered the
sepsis pathway, leaving 106 patients in the intervention arm
and 52 patients in the control group for analysis. Among them,
6 patients were excluded from appropriateness analysis due to
unassessable baseline appropriateness (Figure 1).
Notable baseline differences between the intervention and
control group were prior antibiotic and day of the week trigger
(ie, Friday or Saturday) (Table 1). No advanced-care directives
were in place that limited antibiotic management.
figure 1. Schematic flow diagram of inpatient sepsis pathway study enrollment and analysis.
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Antibiotic Appropriateness
Antibiotic appropriateness at the time of the sepsis pathway
trigger was assessable in 152 of 158 patients and was found to
be appropriate in 80 of 152 (53%) and inappropriate for 72 of
152 (47%). There was no difference in overall initial antibiotic
appropriateness between the intervention and the control
group (Table 1). At 48 hours after sepsis pathway trigger,
antibiotic management was appropriate in 97 of 102 (95%)
intervention patients compared to 38 of 50 (76%) controls
(relative risk [RR], 1.25; 95% confidence interval [CI], 1.06–
1.47; P< .01). The difference remained after adjusting for
baseline differences in the day of the week of the trigger
(ie, Friday or Saturday versus another day of the week) and
pretrigger antibiotics (adjusted RR, 1.24; 95% CI, 1.04–1.47;
P= .035). There was no difference in 48-hour appropriateness
when analysis was restricted to those with a diagnosis of sepsis.
In this subanalysis, 60 of 61 (98%) and 27 of 30 (90%) received
appropriate antibiotics at 48 hours in the intervention
and control groups, respectively (P= .09). The interrater
agreement between 3 ID authors for assessment of appro-
priateness was 95%.
Sepsis Diagnosis
Overall, 61 of 106 patients in the intervention group (58%)
and 30 of 52 controls (58%) had a diagnosis of sepsis. Severe
sepsis was present in 8% of intervention patients compared to
12% of controls (P= .54). Diagnostic test sampling did not
differ markedly; blood cultures were collected in 90% and
serum lactate in 48% of patients (Table 1).
Intervention Recommendations and Concordance
In the intervention group, 134 IDAT recommendations were
made for 94 patients, among whom 125 (93%) were followed
or partially followed (Table 2). IDAT recommendations
included cessation or de-escalation of antibiotics in 56 of 106
patients (53%) and increasing antibiotic spectrum in 19 of 106
patients (18%). Diagnostic investigations were recommended
table 1. Baseline Characteristics of Patients Triggering the Sepsis Pathway
Baseline Characteristics
Intervention
N = 106 (%)
Control
N= 52 (%) P Valuea
Female 55 (52) 21 (40) .17
Age, y, median (1st and 3rd quartiles) 70.5 (64.7, 82.4) 71.7 (64.0–84.4) .99
Mean APACHE II score (SD) 16.2 (6.9) 16.7 (6.5) .68
Positive blood culture 23 (22) 9 (17) .52
Blood cultures taken at trigger time 98 (92) 46 (88) .41
Lactate taken at trigger time 46 (43) 30 (58) .09
Source of presumed sepsis .82
Respiratory 32 (30) 15 (29)
Urinary 22 (21) 11 (21)
Biliary or gastrointestinal 18 (17) 7 (13)
Neutropenic 8 (8) 4 (8)
Skin or surgical site 6 (6) 3 (6)
Gynecological or genital 4 (4) 0 (0)
Orthopedic 1 (1) 0 (0)
Unknown 15 (14) 12 (23)
Sepsisb 61 (58) 30 (58) .99
Severe sepsisc 9 (8) 6 (12) .54
Antibiotics prescribed before trigger 75 (71) 26 (50) .044
Trigger on Friday or Saturday 15 (14) 21 (40) <.01
Initial antibiotic appropriatenessd 52 (51) 28 (56) .56
Optimal 21 (21) 8 (16)
Adequate 31 (30) 19 (38)
Suboptimal 35 (34) 21 (42)
Inadequate 15 (15) 2 (4)
NOTE. APACHE II, Acute Physiology and Chronic Health Evaluation II; SD, standard deviation.
aP value from test for difference between intervention and control baseline characteristics.
bDefined as infection with 2 or more systemic inflammatory response syndrome (SIRS) criteria6 and is
inclusive of severe sepsis
cDefined as sepsis with organ dysfunction6
dImmediate postsepsis trigger appropriateness (adequate + optimal) according to NAPS criteria,10 determined
in those assessable for appropriateness (intervention n= 102; controls n= 50).
4 infection control & hospital epidemiology
https://www.cambridge.org/core/terms. https://doi.org/10.1017/ice.2017.139
Downloaded from https://www.cambridge.org/core. Yeshiva University Libraries, on 19 Jul 2017 at 08:02:29, subject to the Cambridge Core terms of use, available at
in 40 of 106 patients (38%). Patients without sepsis were more
likely to receive a recommendation to cease an antibiotic
(29 vs 7; P< .01) and to have further investigation (14 vs 20;
P< .05) and were less likely to receive the recommendation
‘increase spectrum’ (1 vs 19; P< .01). Prescriptions for
ceftriaxone and pipericillin-tazobactam, the most frequently
prescribed antibiotics, were reduced in the intervention group
from 34% (46 of 137) to 27% (25 of 94) and were increased in
the control patients from 25% (13 of 52) to 44% (28 of 64) at
48 hours.
Clinical Outcomes
Clinical outcomes were similar in the intervention and control
groups (Table 3). Overall, 24 patients (15%) were admitted to
the ICU and 15 patients (9%) received a formal ID consult. The
difference in mortality between the intervention (14 of 106;
13%) and control group (9 of 52; 17%) was not statistically
significant (P= .49). The median LOS was 18 days in the control
group and 13 days in the intervention group (P= .14). Overall
median duration of antibiotic therapy was 9 days for the inter-
vention patients compared to 10.5 days for controls (P= .34).
discussion
This study demonstrates that appropriateness of antibiotic
prescribing at 48 hours for non-ICU inpatients triggering the
sepsis pathway was significantly improved by early IDAT
review. This finding is consistent with other findings that ID
intervention improves appropriate antibiotic prescribing in
acute care.12–14 In the patient subgroup with confirmed sepsis,
the rate of appropriate antibiotic therapy in patients at 48 hours
were comparable, suggesting that the greatest impact from
IDAT intervention was on antibiotic management of those
patients triggering the pathway who did not have sepsis. This
highlights the importance of monitoring quality sepsis inter-
ventions for unintended consequences and a role for AMS.
Initial antibiotic management was inappropriate in almost
half of the study population. Optimization was predominantly
achieved through de-escalation; an increase in spectrum was the
next most frequent recommendation. Suboptimal initial anti-
biotic prescribing may be due to a combination of poor pathway
specificity, overattribution of the diagnosis of sepsis in deterio-
rating patients, and protocol-driven time pressure to administer
antibiotics within 60 minutes for suspected sepsis. Similar rates
of hospital inpatient infection misdiagnosis were found to be
strongly associated with inappropriate antibiotic use.15
The relatively high rate of blood culture sampling suggests
effective junior doctor sepsis pathway process training. How-
ever, protocolizing inpatient sepsis antibiotic management is
difficult given that many patients may already be receiving
therapy. Junior doctors (ie, with the least experience) are
typically required to make acute inpatient assessments and
management decisions, often with less on-site senior medical
support compared with emergency departments and ICUs.
The imperative for early antibiotic initiation in sepsis man-
agement pathways exacerbates this scenario. While appro-
priate antibiotic therapy should be commenced as early as
possible and within 60 minutes for severe sepsis and septic
shock,3 there is little evidence demonstrating the benefit of
early antibiotic administration in uncomplicated sepsis.4,5,17
Thus, it may be more judicious for sepsis pathways to focus on
early antibiotic delivery (<60 minutes) for cases suspected of
severe sepsis and septic shock, while further timely investiga-
tion should be undertaken for cases suspected of uncompli-
cated sepsis.
Antibiotic review and rationalization post sepsis trigger is
recommended in sepsis pathways,7 but in clinical practice,
these may not be prioritized. Despite a comprehensive
hospitalwide AMS program16 and intensive sepsis pathway
preimplementation preparation, IDAT intervention facilitated
a further significant sizeable improvement in antibiotic
prescribing over standard inpatient care beyond the sepsis
trigger. Inadequate de-escalation and overprescription of
broad-spectrum antibiotics may represent avoidable harm and
is important to monitor antibiotic administration in sepsis
interventions. AMS efforts could be integrated with sepsis
pathway protocols to optimize appropriate initial and ongoing
table 2. Compliance with Infectious Diseases Advanced Trainee
(IDAT) Recommendations in the Intervention Group
IDAT Recommendationa No. Made No. Followed (% )
Total 134 125 (93)
Cease antibiotic 36 32 (89)
Decrease spectrum 20 18 (90)
Increase spectrum 19 18 (94)
Escalation plan 10 10 (100)
Change to oral antibiotics 2 2 (100)
Change therapy due to safety 1 1 (100)
Change dose 6 6 (100)
Investigation suggested 40 38 (95)
No recommendation needed 12 …
a>1 intervention possible per patient.








No. (%)a P Value
ICU admission 16 (15) 8 (15) .96
Formal ID consult 11 (10) 4 (8) .59
Mortality 14 (13) 9 (17) .49
Mortality if confirmed sepsis 9 (15) 5 (17) .52
Length of stay, d, median
(1st, 3rd quartiles)
13 (7, 27) 17.5 (10, 29) .14
Length of therapy, d, median
(1st, 3rd quartiles)
9 (5, 15) 10.5 (5, 16.5) .34
NOTE. ICU, intensive care unit; ID infectious diseases.
aUnless otherwise specified.
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antibiotic therapies. Appropriate, guideline-adherent empirical
antibiotic management has been shown to be associated with a
relative risk reduction for mortality of 35% (relative risk, 0.65;
95% CI, 0.54–0.80; P< .0001).18
Secondary outcomes including length of therapy, LOS, ICU
admission, formal ID consultation, and mortality were not
significantly different between the intervention and control
groups. However, this study was not powered to detect a sta-
tistically significant difference in clinical outcomes. These clin-
ical outcomes were used to detect potential harms arising from
the intervention. Overall mortality of 15% is consistent with
other reported inpatient sepsis mortality (15%–35%)19,20 and
was not different among patients diagnosed with sepsis.
Although there was no difference in LOS, emerging evidence
suggests that improving antibiotic appropriateness8,21 and ID
specialist review13,14 may impact this outcome in a larger study.
This study had several limitations including study size,
duration, generalizability, and selection bias. Although the
study population was small, it was adequately powered to
detect the primary outcome of a significant difference in
antibiotic appropriateness in patients 48 hours after triggering
the sepsis pathway. Standardized national criteria for antibiotic
appropriateness10 were utilized in this study; however,
observer bias was a potential risk. This was addressed by using
additional blinded assessments by 2 senior ID coauthors,
which demonstrated high interrater agreement.
The study intervention was a brief case review by 1 IDAT in
a single institution. Therefore, benefits may be operator
dependent and are not necessarily generalizable. PDSA cycles
may generate different interventions in other settings. Addi-
tionally, the capacity of both AMS and quality programs
depend on the institution’s resources. To remain cost neutral,
additional time required for the IDAT intervention during this
study was taken from routine AMS responsibilities. Inclusion
of early IDAT sepsis review within AMS programs may prove
to be an efficient use of AMS resources, particularly if it is
prioritized for higher-acuity patients.
This study was not randomized; therefore, selection bias is a
limitation. The small sample size restricts the number of
potential baseline differences that can be adjusted for. Never-
theless, those differences considered most likely to influence
group allocation and appropriateness, prior antibiotics and
triggering the pathway on a Friday or Saturday, were also
statistically significant. After adjusting for these, the significance
of the impact of IDAT intervention on antibiotic appropriateness
remained. Nevertheless, the need to ensure ongoing optimal
antibiotic management ‘after hours’ is highlighted by this study
and other research demonstrating an association between
weekend day admissions and adverse clinical outcomes.22 Other
baseline differences were unlikely to be clinically significant for
the primary study end point, antibiotic appropriateness.
The difficulty with achieving diagnostic specificity in
sepsis is acknowledged in the recent change in the Interna-
tional Consensus Definitions for Sepsis and Septic Shock
(SEPSIS-3).23 New sepsis definitions published after the
completion of this study hone the criteria for sepsis toward
organ dysfunction as a manifestation of an injurious host
response to infection rather than focusing on systemic
inflammation. Application of SEPSIS-3 criteria in this study
would have improved specificity and therefore may have
reduced unnecessary exposure to broad-spectrum antibiotics.
In Australia, improvement in emergency department sepsis
recognition and care followed implementation of the CEC
emergency department sepsis pathway in 2011.19 However,
a significant rise in non-ICU inpatient sepsis mortality was also
observed, the cause of which was unclear.19 Benefits of adult
inpatient sepsis pathways have yet to be established. Further
CEC inpatient sepsis pathway revision has occurred since this
study was conducted.24 An evaluation of the impact of these
pathways on much needed improvement in inpatient sepsis
recognition and management is highly anticipated.
In conclusion, hospital inpatient sepsis remains a clinical
challenge. Lack of sepsis diagnostic specificity hinders clinical
sepsis pathway implementation and may drive inappropriate
antibiotic use. Infectious disease AMS significantly improved
antibiotic appropriateness for non-ICU inpatients with sus-
pected sepsis, with the greatest impact on those patients who
were misdiagnosed. Hospitals implementing sepsis pathways
should evaluate their diagnostic specificity and patients’ anti-
biotic exposure and consider how AMS may optimize these.
Larger prospective studies are needed to validate these findings
and evaluate clinical outcomes.
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